Antibody drug conjugate manufacturing: linkers, ratio and analysis

Specifying the programme

1. Choose the linker against the release mechanism you want. Cleavable linkers release payload under conditions found inside cells; non cleavable linkers release only on antibody degradation. Stability in circulation and release at the target are the two ends of the same trade, and the choice shapes everything downstream.
2. Specify the distribution, not just the average ratio. An average drug to antibody ratio can be produced by many different mixtures, and the unconjugated and heavily conjugated species behave differently in the body. The specification has to cover the distribution.
3. Decide stochastic against site specific conjugation early. Conventional conjugation is simple and produces a heterogeneous product. Site specific approaches produce a defined species and require antibody engineering and often a new process. Deciding late means redoing the antibody.
4. Set limits for free drug and related impurities. Unconjugated payload is a potent impurity with its own limit and its own assay. It must be controlled at release and monitored on stability.
5. Treat the payload as a containment problem. Highly potent compounds impose occupational exposure limits, containment engineering, cleaning verification and waste handling. Not every partner with biologics capacity can take this work.
6. Build the analytical package before the batch. Ratio and distribution, free drug, aggregation, identity, potency and stability indicating methods. These take longer to develop than the conjugation itself and are the usual critical path.

Heterogeneity is the characterisation problem

A conventionally conjugated product is a mixture of species differing in load and in site, and every analytical method sees that mixture differently. Characterising it properly means measuring the distribution, not summarising it.

That is why site specific approaches keep gaining ground: a defined species is easier to make consistently, easier to characterise and easier to defend, even though the route to it is longer.

The facility question, and choosing among adc manufacturers

Handling a highly potent payload requires containment, exposure monitoring and cleaning verification that most biologics facilities do not have. It narrows the list of possible partners considerably and it should narrow it at the start of the search.

Ask for the occupational exposure limit they work to and how they verify cleaning between products. A partner without a clear answer is not a candidate.

mab manufacturing, and the shape of the process

Monoclonal antibody manufacture is the most standardised process in biologics, which is why it is quoted quickly: a CHO cell line from a bank, fed-batch culture in a stirred tank, harvest by depth filtration or centrifugation, protein A capture, low pH viral inactivation, one or two polishing steps by ion exchange or mixed mode, viral filtration, ultrafiltration and diafiltration into formulation, then fill. Titres of several grams per litre are routine. What differs between programmes is the product quality attributes and the specification, not the unit operations.

A crbn antibody and the ligase a degrader recruits

Cereblon is the substrate receptor a molecular glue degrader hijacks, so a crbn antibody is used to confirm expression in a line before a degrader experiment and to check it has not been lost in a resistant one, which is a common resistance mechanism. Its own level is fairly stable, so the informative readout is the target protein's disappearance rather than the ligase's abundance.

antibody oligonucleotide conjugates and what they are for

antibody oligonucleotide conjugates join a binder to a nucleic acid, either to deliver an oligonucleotide therapeutic to a cell type or to barcode an antibody for a sequencing readout, and the two uses have different requirements. Conjugation site, the ratio achieved and the stability of the linker in serum are the specifications, and free oligonucleotide is the impurity that matters most.

An mrp2 antibody and a drug efflux transporter

MRP2 exports conjugated drugs across the canalicular membrane, so an mrp2 antibody is read as apical membrane staining in a polarised cell or tissue and location rather than level is the finding. It is a large multipass glycoprotein, so gentle lysis and a membrane fraction apply, and a functional transport assay is what turns expression into a statement about efflux.

A dhodh antibody and a target with a well known inhibitor

DHODH sits in the inner mitochondrial membrane and is the target of established inhibitors, so a dhodh antibody is read with a mitochondrial marker and the functional readout is pyrimidine rescue by uridine, which is the control that makes an on target claim. Expression differences between lines are the usual comparison and need a stated loading reference.

An adam12 antibody and a sheddase with a pro form

ADAM12 is made as a proenzyme and processed to an active form, so an adam12 antibody shows two masses and only one is active, which is why the expected bands belong in the method. It is also secreted in a soluble variant that appears in medium and in serum, and which species an assay reports is the question that decides a clinical figure.

Common questions

Why do antibody drug conjugate linkers matter more than the payload?

Because payload potency is largely known while linker behaviour decides where that potency is delivered. Premature release produces systemic toxicity; excessive stability produces no effect at the target. The therapeutic window is largely a linker property.

What does drug to antibody ratio actually tell you?

An average. Two batches with the same average can contain very different proportions of unconjugated and heavily loaded species, which differ in clearance and toxicity. The distribution is the meaningful specification.

Is site specific conjugation worth it?

It gives a homogeneous product that is easier to characterise and often has a better profile, at the cost of antibody engineering and a more involved process. For programmes intending to go far, it is increasingly the default.

What should a conjugation partner demonstrate?

Containment appropriate to the payload with occupational monitoring, an established conjugation platform with distribution control, free drug and aggregation analytics in house, and cleaning verification between products.

Browse by service class

• Compare Gene synthesis on advertised prices